1) GH001 Harvey (2010) Extrapituitary growth hormone. Endocrine 38:335–359. (link)

2) GH002 Subramani et al (2017) Role of Growth Hormone in Breast Cancer. Endocrinology 158(6):1543–1555. (link)

3) GH003 Subramani et al (2014) Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma. E xperimental & Molecular Medicine 46. (link)

4) GH004 Kaulsay et al (1999) Autocrine Stimulation of Human Mammary Carcinoma Cell Proliferation by Human Growth Hormone Experimental Cell Research 250, 35–50. (link)

5) GH005 Sustarsic at al. (2013) Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment. Biochemical and Biophysical Research Communications 441(1):144-50. (link)

6) GH006 Kong et al (2016) Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma. Oncotarget 7(20): 29465-79. (link)

7) GH007 Di Bella et al. (2018) The over-expression of GH/GHR in tumour tissues with respect to healthy ones confirms its oncogenic role and the consequent oncosuppressor role of its physiological inhibitor, somatostatin: a review of the literature. Neuroendocrinology Letters 39(4): 101-109. (link)

8) GH008 Basu R. and Kopchick J.J (2019) The effects of growth hormone on therapy resistance in cancer. Cancer Drug Resistance 2:827-846. (link)

9) GH009 Zhu et al. 2020 Growth hormone receptor promotes breast cancerprogression via the BRAF/MEK/ERK signaling pathway. FEBS Open Bio 10(6):1013-1020 (link)

10) GH010 Basu et al. (2025) “L’azione dell’ormone della crescita come bersaglio nel cancro: significato, meccanismi e possibili terapie – Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies”. Endocrine Reviews 46(2): 224–280. (link) (video)

11) GH011 Recouvreux et al. (2017) “Regolazione del Recettore Androgeno dell’Ormone della Crescita Locale nelle Cellule del Carcinoma Prostatico – Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells”. Endocrinology, 158(7):2255–2268. (link) (video)

1) GHRH001 Khanlari et al. (2018) “Espressione di GHRH-R, un biomarcatore potenzialmente bersaglio, nel carcinoma mammario triplo negativo – Expression of GHRH-R, a Potentially Targetable biomarker, in Triple-negative Breast Cancer”. Applied Immunohistochemistry and Molecular Morphology 26(1):1-5. (link)

11) GHRH002 Perez et al. (2012) “Gli antagonisti dell’ormone di rilascio dell’ormone della crescita sopprimono la crescita tumorale in vivo e l’espressione genica nei tumori al seno triplo negativi – Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers”. Oncotarget 3:988-997. (link)

12) GHRH003 Koster et al. (2009) “I tumori al seno triplo negativi esprimono recettori per l’ormone di rilascio dell’ormone della crescita (GHRH) e rispondono agli antagonisti del GHRH con l’inibizione della crescita” pubblicato sulla rivista Breast Cancer Research and Treatment è disponibile sul blog. (link)

13) GHRH004 Montero-Hidalgo et al. (2025) “Aggiornamento sulla regolazione del GHRH e le sue azioni sulla secrezione di GH in salute e malattia – Update on regulation of GHRH and its actions on GH secretion in health and disease”. Reviews in Endocrine and Metabolic Disorders, online 21 gennaio 2025. (link)

14) GHRH005 Gesmundo et al. (2024) “Ormone di rilascio dell’ormone della crescita e cancro – Growth hormone-releasing hormone and cancer”. Reviews in Endocrine and Metabolic Disorders 26: 443–456. (link)

16) GHRH006 Granata et al. (2025) “Ormone di rilascio dell’ormone della crescita e i suoi analoghi in salute e malattia – Growth hormone-releasing hormone and its analogues in health and disease.” Nature Reviews Endocrinology 21(3):180-195. (link) (video)